About Anjan Drug
Anjan Drug is a company based in Chennai (India) founded in 1990 by C Kalaichelvan was acquired by PAG in October 2020. Anjan Drug has raised $5.28 million across 1 funding round from investors including Evolvence, C Kalaichelvan and K Lalitha. The company has 297 employees as of April 07, 2024. Anjan Drug offers products and services including Valproic Acid, Sodium Valproate, Divalproex Sodium, Magnesium Valporate, and Gabapentin. Anjan Drug operates in a competitive market with competitors including Laurus Labs, Symbiotec, Provepharm Life Solutions, Beijing Biostar Technologies and SeQuent, among others.
- Headquarter Chennai, India
- Employees 297 as on 07 Apr, 2024
- Founders C Kalaichelvan
- Stage Minicorn
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Anjan Drug Private Limited
- Date of Incorporation 01 Aug, 1990
- Jurisdiction Chengalpattu Dt, Tamil Nadu, India
-
Annual Revenue
$36.37 M (USD)60.61as on Mar 31, 2023
-
Net Profit
$6.91 M (USD)123as on Mar 31, 2023
-
EBITDA
$9.83 M (USD)112.52as on Mar 31, 2023
-
Total Equity Funding
$5.28 M (USD)
in 1 rounds
-
Latest Funding Round
$5.28 M (USD), Series A
Jun 05, 2009
-
Investors
Evolvence
& 5 more
-
Employee Count
297
as on Apr 07, 2024
-
Acquired by
PAG
(Oct 12, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Anjan Drug
Anjan Drug offers a comprehensive portfolio of products and services, including Valproic Acid, Sodium Valproate, Divalproex Sodium, Magnesium Valporate, and Gabapentin.
Active ingredient used in pharmaceutical treatments for neurological disorders.
Key component for antiepileptic and mood-stabilizing medications.
Compound for managing seizures and bipolar disorder in drugs.
Ingredient in formulations for epilepsy and psychiatric conditions.
Active substance for treating nerve pain and seizures.
People of Anjan Drug
Unlock access to complete
Funding Insights of Anjan Drug
Anjan Drug has successfully raised a total of $5.28M through 1 strategic funding round. The most recent funding activity was a Series A round of $5.28 million completed in June 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Anjan Drug
Anjan Drug has secured backing from 6 investors, including institutional, angel, and venture fund investors. Prominent investors backing the company include Evolvence, C Kalaichelvan and K Lalitha.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Alternative investment firm
|
Locked | Locked | Locked | |
|
Private equity investments are managed across multiple sectors.
|
Locked | Locked | Locked | |
|
Private equity investments in India are managed by CX Partners.
|
Locked | Locked | Locked |
Investor details for Anjan Drug
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Anjan Drug
Investment portfolio details for Anjan Drug
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Anjan Drug
Detailed financials for Anjan Drug
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Anjan Drug Comparisons
Peer comparison for Anjan Drug
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Anjan Drug
Anjan Drug operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Laurus Labs, Symbiotec, Provepharm Life Solutions, Beijing Biostar Technologies and SeQuent, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical and biotechnology company
|
|
| Locked | Locked | Locked |
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
|
|
| Locked | Locked | Locked |
APIs and drug products are developed and valorized in pharmaceuticals.
|
|
| Locked | Locked | Locked |
APIs, intermediates, and biochemical reagents are developed and manufactured.
|
|
| Locked | Locked | Locked |
APIs are developed and manufactured for therapeutic areas.
|
|
| Locked | Locked | Locked |
Contract development, manufacturing, and analytical services for APIs are offered.
|
Detailed competitors of Anjan Drug
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Anjan Drug
Complete news archive for Anjan Drug
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Anjan Drug
Anjan Drug was founded in 1990 and raised its 1st funding round 19 years after it was founded.
Anjan Drug is headquartered in Chennai, India. It is registered at Chennai, Tamil Nadu, India.
Anjan Drug is a funded company, having raised a total of $5.28M across 1 funding round to date.
As of Apr 07, 2024, the latest employee count at Anjan Drug is 297.
Annual revenue of Anjan Drug is $36.37M as on Mar 31, 2023.
Founded in 1990 in Chennai, India, active pharmaceutical ingredients are produced by Anjan Drug within the pharmaceutical sector, with operations centered on central nervous system treatments. Epilepsy drugs are manufactured as a US-FDA approved producer, adhering to US, European, and British Pharmacopeia standards. Approvals for US and Canadian DMFs, along with a European Certificate of Suitability, have been secured. Clients such as Abbott, Sanofi-Aventis, Mylan, and Actavis are served.
Anjan Drug's top competitors include Laurus Labs, Symbiotec and Beijing Biostar Technologies.
Anjan Drug offers Valproic Acid, Sodium Valproate, Divalproex Sodium, Magnesium Valporate, and Gabapentin.
Anjan Drug has 6 investors. Key investors include Evolvence, C Kalaichelvan, K Lalitha, PAG, and Samara Capital.
The valuation of Anjan Drug is $9.07M as of Jun 2009.